Clinical Topics & News

Adalimumab for the Treatment of Pityriasis Rubra Pilaris: A Case Report

Author and Disclosure Information

Pityriasis rubra pilaris (PRP) is a chronic papulosquamous eruption of the skin characterized by follicular hyperkeratosis, salmon pink scaly plaques with islands of unaffected skin, and palmoplantar keratoderma. Widely used oral systemic and topical treatments are not greatly effective. We present a 62-year-old man with PRP of 2 years’ duration who used routine topical treatments, oral retinoids, and UV therapy without improvement, but his symptoms greatly improved with the initiation of adalimumab.


 

Recommended Reading

Using CORRONA Registry Data to Treat Rheumatic Diseases
MDedge Dermatology
Antibiotics Helpful in Chlamydia-Induced Reactive Arthritis
MDedge Dermatology
Thalidomide Remains a Good Choice for Refractory Cutaneous Lupus
MDedge Dermatology
Brodalumab Knocks Psoriasis Out of Park
MDedge Dermatology
Adalimumab May Be Best Anti-TNF for Psoriasis in Obesity
MDedge Dermatology
Experience Proved Rituximab Best for Vasculitis
MDedge Dermatology
Psoriasis Plus Diabetes Equals Heightened Vascular Risk
MDedge Dermatology
EULAR's Lupus Nephritis Guidelines Emphasize Early Biopsy
MDedge Dermatology
Psoriasis Flares Rapidly Postpartum
MDedge Dermatology
Psoriasis: Short-Course Clobetasol Enhances Etanercept Outcomes
MDedge Dermatology